Multicolor Fluorescence-Based Approaches for Imaging Cytokine-Induced Alterations in the Neovascularization, Growth, Metastasis, and Apoptosis of Murine Neuroblastoma Tumors

Neuroblastoma is one of the most common solid tumors in children. The prognosis of patients with advanced neuroblastoma is poor overall despite standard therapeutic modalities and has stimulated substantial interest in the potential role for biologics such as immunotherapeutic and/or antiangiogenic agents for the treatment of neuroblastoma. To facilitate preclinical investigation of the efficacy and mechanisms of action of new biologic agents for the treatment of neuroblastoma, a comprehensive panel of disease-specific fluorescence-based model systems has been developed by our group to image the growth, neovascularization, metastasis, and apoptosis of neuroblastoma tumors. These model systems use fluorescent proteins to monitor cytokine-induced alterations in the growth and metastasis of neuroblastoma and allow for monitoring and/or quantitation of even minimal residual disease that is localized to visceral organ sites such as the liver, lung, and/or bone marrow. Further, based on the differential spectra of red fluorescent protein, green fluorescent protein (GFP), and agents such as 4′-6-diamidino-2-phenylindole (DAPI) (blue) and fluorescein isothiocyanate–dextran (green), multicolor systems have now been established by our group that allow for combined assessment of parameters, including the macroscopic relation of tumors to their associated vasculature and, within tissue sections, simultaneous quantitation of tumor neovascularization and evaluation of therapy-induced apoptosis within the tumor and vascular endothelial compartments. Further, by engineering cells to express specific mediators of apoptosis that have been linked to GFP (ie, BID-EGFP), these systems can also be used to dissect mechanisms by which neuroblastoma cells are induced to undergo apoptosis in vitro as well as in vivo. Collectively, these model systems provide important tools for investigation of the biology of neuroblastoma tumors and evaluation of mechanisms that mediate the regression of these tumors in response to novel therapeutic agents, including cytokines such as interleukin-12.

[1]  S. Gillies,et al.  Enhanced Activity of Hu14.18-IL2 Immunocytokine against Murine NXS2 Neuroblastoma when Combined with Interleukin 2 Therapy , 2004, Clinical Cancer Research.

[2]  J. Ward,et al.  Complete Regression of Established Spontaneous Mammary Carcinoma and the Therapeutic Prevention of Genetically Programmed Neoplastic Transition by IL-12/Pulse IL-2: Induction of Local T Cell Infiltration, Fas/Fas Ligand Gene Expression, and Mammary Epithelial Apoptosis1 2 , 2001, The Journal of Immunology.

[3]  Michael Bouvet,et al.  An imageable highly metastatic orthotopic red fluorescent protein model of pancreatic cancer , 2004, Clinical & Experimental Metastasis.

[4]  D. Ribatti,et al.  Antiangiogenic strategies in neuroblastoma. , 2005, Cancer treatment reviews.

[5]  A. Rademaker,et al.  Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Jenney Principles and Practice of Pediatric Oncology , 1994 .

[7]  Eugene S. Kim,et al.  Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Simone Fulda,et al.  Apoptosis Signaling in Tumor Therapy , 2004, Annals of the New York Academy of Sciences.

[9]  W. Stallcup,et al.  Early Contribution of Pericytes to Angiogenic Sprouting and Tube Formation , 2004, Angiogenesis.

[10]  S. Kimura,et al.  Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. , 2005, Cancer letters.

[11]  K. Matthay,et al.  Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Junying Yuan,et al.  Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.

[13]  K K Matthay,et al.  Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid , 1999 .

[14]  A. Theofilopoulos,et al.  Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Wigginton,et al.  IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. , 2001, The Journal of clinical investigation.

[16]  P. Pizzo,et al.  Principles and Practice of Pediatric Oncology , 1989 .

[17]  R. Hoffman,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Review Gfp Imaging in Vivo Green Fluorescent Protein Imaging of Tumour Growth, Metastasis, and Angiogenesis in Mouse Models , 2022 .

[18]  N. Rubio,et al.  Different effect of paclitaxel on primary tumor mass, tumor cell contents, and metastases for four experimental human prostate tumors expressing luciferase. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  John M Maris,et al.  The biologic basis for neuroblastoma heterogeneity and risk stratification , 2005, Current opinion in pediatrics.

[20]  György Hajnóczky,et al.  Rapid Kinetics of tBid-induced Cytochrome c and Smac/DIABLO Release and Mitochondrial Depolarization* , 2002, The Journal of Biological Chemistry.

[21]  J. Nuchtern,et al.  Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes. , 2000, Cancer research.

[22]  K. Hillan,et al.  Neutralizing anti‐vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo , 1998, The Prostate.

[23]  Xiaodong Wang,et al.  Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.

[24]  G. Mohapatra,et al.  Targeted expression of MYCN causes neuroblastoma in transgenic mice , 1997, The EMBO journal.

[25]  D. Green,et al.  The Pathophysiology of Mitochondrial Cell Death , 2004, Science.

[26]  Meng Yang,et al.  Real‐time whole‐body imaging of an orthotopic metastatic prostate cancer model expressing red fluorescent protein , 2005, The Prostate.

[27]  R. Seeger,et al.  Human NKT Cells Mediate Antitumor Cytotoxicity Directly by Recognizing Target Cell CD1d with Bound Ligand or Indirectly by Producing IL-2 to Activate NK Cells1 , 2001, The Journal of Immunology.

[28]  S. Nilsson,et al.  Imbalance of the mitochondrial pro- and anti-apoptotic mediators in neuroblastoma tumours with unfavourable biology. , 2005, European journal of cancer.

[29]  M. Lotze,et al.  Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo. , 2003, Journal of pediatric surgery.

[30]  Hua Yu,et al.  Anti-CD40 Antibody Induces Antitumor and Antimetastatic Effects: The Role of NK Cells1 , 2001, The Journal of Immunology.

[31]  R. D'Amato,et al.  Inhibition of angiogenesis in vivo by interleukin 12. , 1995, Journal of the National Cancer Institute.

[32]  Dai Fukumura,et al.  Dissecting tumour pathophysiology using intravital microscopy , 2002, Nature Reviews Cancer.

[33]  J. Djeu,et al.  Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. , 1994, Blood.

[34]  S. Gillies,et al.  Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. , 2003, Blood.

[35]  S. Paris,et al.  Metastasis models: the green fluorescent revolution? , 2004, Carcinogenesis.

[36]  Tomoko Nakanishi,et al.  ‘Green mice’ as a source of ubiquitous green cells , 1997, FEBS letters.

[37]  J. Tschopp,et al.  Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. , 2000, Cancer research.

[38]  F. Behm,et al.  Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN , 2000, Nature Medicine.

[39]  D. Newmeyer,et al.  Mitochondria Releasing Power for Life and Unleashing the Machineries of Death , 2003, Cell.

[40]  R. Khosravi‐Far Death receptor signals to the mitochondria , 2004, Cancer biology & therapy.

[41]  V. Mootha,et al.  tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. , 2000, Genes & development.

[42]  S. Cohn,et al.  Advances in the diagnosis and treatment of neuroblastoma , 1998, Current opinion in oncology.